BFEC
KYMR icon

Benjamin F. Edwards & Company’s Kymera Therapeutics KYMR Stock Holding History

Benjamin F. Edwards & Company’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-87
Closed -$3K – 2191
2024
Q1 		$3K Buy
+87
New +$3.11K ﹤0.01% 1967

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Benjamin F. Edwards & Company's KYMR Position: Q2 2024 in Review

Benjamin F. Edwards & Company sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 87 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in KYMR in Q1 2024 and held it in 1 quarter. The position peaked at $3K in Q1 2024. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Benjamin F. Edwards & Company reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 87 Kymera Therapeutics shares in Q2 2024, an estimated $3K.
  • Benjamin F. Edwards & Company first reported a position in Kymera Therapeutics in Q1 2024 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Kymera Therapeutics position peaked at $3K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.